EP0906278B1 - 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones - Google Patents
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones Download PDFInfo
- Publication number
- EP0906278B1 EP0906278B1 EP97928831A EP97928831A EP0906278B1 EP 0906278 B1 EP0906278 B1 EP 0906278B1 EP 97928831 A EP97928831 A EP 97928831A EP 97928831 A EP97928831 A EP 97928831A EP 0906278 B1 EP0906278 B1 EP 0906278B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- alkyl
- aryl
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC=CC=C(C)N([C@@]([C@]1[C@@](CO)O)C(C=CC=C*)=CC)C1=O Chemical compound CC=CC=C(C)N([C@@]([C@]1[C@@](CO)O)C(C=CC=C*)=CC)C1=O 0.000 description 6
- YHJRDZZBKYDUTC-HHBXCQJQSA-N CC(C=C1)C=C1C(/C=C/[C@H](C(c(cc1)ccc1OCc1ccccc1)N1/C(/C)=C/C=C\C)C1=O)=O Chemical compound CC(C=C1)C=C1C(/C=C/[C@H](C(c(cc1)ccc1OCc1ccccc1)N1/C(/C)=C/C=C\C)C1=O)=O YHJRDZZBKYDUTC-HHBXCQJQSA-N 0.000 description 1
- LALDNCHTBSFGBG-UONBOYCUSA-N CC1C=C([C@H](CC[C@H](C(c(cc2)ccc2O)N2/C(/C)=C/C=C\C)C2=O)O)C=C1 Chemical compound CC1C=C([C@H](CC[C@H](C(c(cc2)ccc2O)N2/C(/C)=C/C=C\C)C2=O)O)C=C1 LALDNCHTBSFGBG-UONBOYCUSA-N 0.000 description 1
- IWNBEFDVKWCBFY-HYARGMPZSA-N Fc(cc1)ccc1/N=C/c(cc1)ccc1OCc1ccccc1 Chemical compound Fc(cc1)ccc1/N=C/c(cc1)ccc1OCc1ccccc1 IWNBEFDVKWCBFY-HYARGMPZSA-N 0.000 description 1
- FRINDQKEXDMUGU-ASXQFSDJSA-N O=C(/C=C/[C@H]([C@@H](C1C=CC(OCc2ccccc2)=CC=C1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F Chemical compound O=C(/C=C/[C@H]([C@@H](C1C=CC(OCc2ccccc2)=CC=C1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F FRINDQKEXDMUGU-ASXQFSDJSA-N 0.000 description 1
- MWDJDSOALBPVEP-ZLUUAVAHSA-N O=C(/C=C/[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F Chemical compound O=C(/C=C/[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F MWDJDSOALBPVEP-ZLUUAVAHSA-N 0.000 description 1
- MFIZBEAAFVTLGB-GKVQRAMASA-N O[C@@H](CC[C@@H](C1)[C@@H](c(cc2)ccc2O)N1c(cc1)ccc1F)c(cc1)ccc1F Chemical compound O[C@@H](CC[C@@H](C1)[C@@H](c(cc2)ccc2O)N1c(cc1)ccc1F)c(cc1)ccc1F MFIZBEAAFVTLGB-GKVQRAMASA-N 0.000 description 1
- KEYVFYMGVLFXQK-DYIKCSJPSA-N O[C@@H](CC[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F Chemical compound O[C@@H](CC[C@H]([C@@H](c(cc1)ccc1OCc1ccccc1)N1c(cc2)ccc2F)C1=O)c(cc1)ccc1F KEYVFYMGVLFXQK-DYIKCSJPSA-N 0.000 description 1
- UEPZDXMEEKCJSP-FKHAVUOCSA-N Oc1ccc(C([C@@H](CCC(c(cc2)ccc2F)=O)C2=O)N2c(cc2)ccc2F)cc1 Chemical compound Oc1ccc(C([C@@H](CCC(c(cc2)ccc2F)=O)C2=O)N2c(cc2)ccc2F)cc1 UEPZDXMEEKCJSP-FKHAVUOCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- This invention provides an improved process for producing azetidinones useful as hypocholesterolemic agents, as disclosed in co-owned, copending PCT Publication WO 95/08532, which is equivalent to U.S. Serial No. 08/617,751, filed March 18, 1996, the disclosure of which is hereby incorporated by reference. More particularly, this invention provides the steps of producing an azetidinone represented by the formula I.
- This invention provides a process for producing a compound of the formula: wherein:
- this process is useful for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-4(S)-(4-fluorophenyl)-2-azetidinone.
- this process comprises reaction of a ⁇ -lactone and an imine to form a ⁇ -lactam, followed by a chiral reduction.
- this invention is directed to a process for preparing a compound of formula I wherein R 1 , R 2 and R 3 are as defined above, comprising
- lower alkyl means straight or branched alkyl chains of 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, “C 1 to C 6 alkyl” means straight or branched alkyl chains of 1 to 6 carbon atoms.
- Lower alkoxy refers to alkoxy groups having 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, “C 1 to C 6 alkoxy” means straight or branched alkoxy chains of 1 to 6 carbon atoms.
- alkenyl means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, “C 1 to C 6 alkenyl” means straight or branched alkenyl chains of 1 to 6 carbon atoms. “Alkynyl” means straight or branched carbon chains having one or more triple bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, “C 1 to C 6 alkynyl” means straight or branched alkynyl chains of 1 to 6 carbon atoms.
- alkylene alkenylene and alkynylene
- Aryl (including substituted aryl) means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g. aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF 3 , amino, alkylamino, dialkylamino and -NO 2 .
- Alkyl means an alkyl group as defined above, in which an aryl group as defined above is substituted for one of the alkyl H atoms, e.g., benzyl, 4-nitro-benzyl' 4-methoxy benzyl and 4-chlorobenzyl.
- Acid means an organic acid such as p-toluene sulfonic acid, trifluoroacetic acid or trifluoromethane sulfonic acid.
- acid means an inorganic acid such as sulfuric acid, hydrochloric acid or phosphonic acid.
- Haldrogenation catalyst means a transition metal or its salt such as Pd/C, Pt/C, Raney nickel, Rh/C, Ru/C, PdO, PtO or (PPh 3 ) 3 RhCl.
- Cycloalkenyl mean a cycloalkane of 4 to 10 carbon atoms with one or more double bonds in the ring.
- Bn means benzyl.
- BnO means benzyloxy.
- Cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms
- cycloalkylene refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. Alternatively, the number of carbon atoms may be specified. Thus, “C 3 to C 6 cycloalkyl” means a saturated carbon ring of 3 to 6 carbon atoms.
- Halogeno or "hal” or “halogen” refers to fluorine, chlorine, bromine or iodine radicals.
- Heteroaryl means a 5- or 6-membered aromatic ring comprising 1 or 2 hetero atoms selected from the groups consisting of nitrogen and oxygen, for example pyridyl, pyrimidyl, imidazolyl, pyrrolyl, furanyl and oxazolyl. All positional isomers for a given heteroaryl group as defined herein are contemplated, for example 2-pyridyl, 3-pyridyl and 4-pyridyl.
- Heteroaryl also means benzofused heteroaryl radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring as defined above; examples are indolyl, quinolyl, quinazolinyl, quinoxalinyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl.
- Ph means phenyl
- Suitable inert organic solvent means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Such solvents used in the various reactions of this invention are identified in the discussion of reaction schemes and in the examples. Typical suitable solvents are halogenated compounds such as chloroform or dichloromethane; heterocyclic compounds such as tetrahydrofuran (THF); 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), dimethylformamide (DMF); dimethylsulfoxide (DMSO), lower alkanols (C 1 -C 6 branched or straight chain alkanols) such as methanol, acetonitrile and carbocyclic aromatics such as toluene.
- halogenated compounds such as chloroform or dichloromethane
- heterocyclic compounds such as tetrahydrofuran (THF); 1,3-dimethyl-3,4,5,6-te
- Lewis acid means an acid such as BF 3 ⁇ etherate, TiCl 4 or AlCl 3 .
- the process of this invention comprises reaction of a ⁇ -lactam and an imine to form a ⁇ -lactam, followed by a chiral reduction according to Reaction Scheme A just below.
- Method A for producing compounds of formula I, wherein the moieties have trans relative stereochemistry, comprises the following steps:
- step (a) of Reaction Scheme A the lactone II is treated in a strong base such as lithium diisopropylamide (LDA) with an imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU, to produce a ⁇ -lactam of formula IV.
- a strong base such as lithium diisopropylamide (LDA)
- imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU
- the reaction can be quenched by an acid such as acetic acid, and a trans ⁇ -lactam of formula IV can be recovered by extraction followed by crystallization. Because trans ⁇ -lactam cyclizes faster than cis ⁇ -lactam, formation of a trans isomer is favored.
- the use of sodium lithium hexamethyldisilyl amide (LiHMDA) as a base favors the formation of a trans ⁇ -lactam of formula IV as opposed to the cis isomer, and is preferred as opposed to Et 2 Zn/LDA or LiN(Pr-i) 2 .
- a lower temperature favors the formation of a trans ⁇ -lactam of formula IV, as opposed to the cis isomer; and thus -35°C, is preferred over -25°C or -15°C.
- a ⁇ -lactam of formula IV is oxidized by treatment with an oxidizing agent such as NalO 4 in a mixture of solvents such as THF and water at a temperature between about 10°C and 25°C, with about 10°C to about 15°C being preferred.
- the ratio of the oxidizing agent, NalO 4 , to diol is as follows: if the diol is present at 1.0 equivalent, then the NalO 4 is present at 1.0-2.0 equivalents, with 1.5 equivalent being preferred.
- the organic solvent for the reaction is a polar aprotic solvent such as acetronitrile or THF.
- the reaction is quenched by adding the reaction mixture to ice water.
- the resulting aldehyde of formula V is extracted and concentrated for use in the next step of the process.
- step (c) an aldehyde of formula V is reacted with the enolether of the formula E in an aprotic anhydrous organic solvent such as toluene in the presence of a Lewis acid such as BF 3 •etherate at a temperature in the range of about -78°C to about -20°C, with about -40°C to about -20°C being preferred.
- a Lewis acid such as BF 3 •etherate
- the resulting aldol reaction can be quenched, for example with a mixture of NaHCO 3 , t-BuOMe and hydrogen peroxide.
- the ratio of the ⁇ -lactam and the enolether can be as follows: if the ⁇ -lactam is present at 1.0 equivalent, then the enolether can be present at 0.9 to 1.2 equivalent with 1.0 equivalent being most preferred.
- the ratio of the ⁇ -lactam and BF 3 •etherate can be as follows: if the ⁇ -lactam is present at 1.0 equivalents, then BF 3 •etherate can be present at 1.0 to 1.5 equivalent, with 1.0 to 1.2 equivalent being preferred.
- the resulting solution containing aldol product is extracted and concentrated for the dehydration step which involves treatment with molecular sieves and an organic acid such as p-toluene sulfonic acid monohydrate.
- an organic acid such as p-toluene sulfonic acid monohydrate.
- the aldol product is present at 1.0 equivalent, then the p-toluene sulfonic acid monohydrate can be present at 0.4 to 0.8 equivalent, with 0.5 to 0.6 equivalent being preferred.
- the solvents which may be employed in this reaction include toluene, t-butyl methyl ether (t-BuOMe), or benzene.
- the molecular sieves which are used in this reaction are 3A or 4A and are present in the reaction at 100% to 200% weight/weight as compared to the aldol compound.
- the reaction temperature is about 35°C to about 100°C, with the range of about 45°C to about 60°C being preferred.
- the resulting compound of formula VI is filtered and concentrated for use in the next step of this process. It will be appreciated that a compound of formula VI is formed with cis and trans stereochemistry. That is, cis and trans about the azetidinone ring as shown by the arrows in these diagrams. Obtaining the compound with the trans stereochemistry is necessary in order to get the desired final products of the invention.
- step (d) the compound of formula VI is hydrogenated by treatment with a hydrogenating agent such as (Ph 3 P) 3 RhCl/H 2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH 3 OH; CH 2 Cl 2 ; toluene; or benzene.
- a hydrogenating agent such as (Ph 3 P) 3 RhCl/H 2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH 3 OH; CH 2 Cl 2 ; toluene; or benzene.
- EtOAc ethyl acetate
- CH 2 Cl 2 ethyl acetate
- the ratio of hydrogenating agent to the compound of formula VI is as follows: if the compound of formula VI is present at 1 mol %, then the hydrogenating agent is present at 0.1 to 10 mol %, with 0.3 mol % being preferred.
- step (e) the compound of formula VII is chirally reduced by reaction in an anhydrous organic solvent such as CH 2 Cl 2 , THF or toluene, in the presence of a borane, such as BH 3 •(CH 3 ) 2 S or borane-THF complex, and a chiral reduction catalyst such as at a temperature in the range of about -30° to about 0°C, with a range of about -20° to about -10°C being preferred.
- the reaction is run for about 1 to about 20 hours, with a range of about 3 to about 10 hours being preferred.
- the ratio of the compound of formula VII to the chiral reduction catalyst is as follows: if the compound of formula VII is present at 1.0 equivalent, then the catalyst is present in a range of about 5 mol % to 100 mol %, with 5 mol % to 10 mol % being preferred. If the compound of formula VII is present at 1.0 equivalent, then the borane (e.g., BH 3 •Me 2 S) is present at 0.7 to 1.0 equivalent, with 0.7 to 0.8 equivalent being most preferred. Concentration, extraction, and crystallization leads to the reduced compound of formula I.
- the borane e.g., BH 3 •Me 2 S
- any one of R 1 , R 2 or R 3 is benzyloxy or alkoxy
- said compounds can be converted to other compounds of formula I wherein R 1 , R 2 or R 3 is hydroxy by methods well known in the art. This is important in the preferred process described below, wherein the desired compound of formula I has a hydroxy group at R 1 , but wherein the hydroxy group must be protected during the process, preferably by a benzyl group.
- the protected compound of formula I is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCO 2 NH 4 under a hydrogen atmosphere: the concentration of Pd/C is 5% to 20% w/w, with 10-15% w/w being preferred.
- the ratio of compound of formula I to Pd/C used is 1.0 equivalent of compound of formula I to 2.0 to 5.0 equivalents of Pd/C, with 3.0 to 4.0 equivalent of Pd/C being preferred.
- hydrogen gas is used in the ranges from 5 psi (pound per square inch) to 100 psi with 20 to 40 psi being preferred.
- the solvents which can be employed at this stage of the reaction include CH 3 OH, ethanol and i-propanol. Alkoxy groups can be converted to hydroxy groups by well-known methods, for example by treatment with a Lewis acid.
- step (a) when trans ⁇ -lactam is formed in step (a), the corresponding cis product is also formed.
- the cis product is present at this stage of the process in an amount of 5% as compared to the trans product.
- the cis product may now be purged out by crystallization.
- the compound of formula VII' is chirally reduced as described above, in the presence of a chiral reduction catalyst to obtain the reduced compound of formula I'
- the compound of formula I' is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCO 2 NH 4 under a hydrogen atmosphere to obtain a compound of formula I"
- a compound of formula VI" may undergo a double hydrogenation step by reaction under hydrogen in the presence of a hydrogenation catalyst such as palladium on carbon to obtain a compound of formula X
- a chiral reduction of the keto group in a compound of formula VI" may be conducted to obtain a compound of formula XI
- the double bond and the BnO group of this compound of formula XI may then be hydrogenated to obtain the compound of formula I"'.
- the compound of formula VI' can be chirally reduced to the compound of formula XI' which can then be hydrogenated to obtain the compound of formula I"
- a compound of formula VI" may be converted by the Noyori reduction, i.e. using the catalyst (R)-Ru(BlNAP)Cl 2 ] 2 .NEt 3 . to obtain the compound of formula I'".
- a compound of formula VI' can be reduced by this method to obtain a compound of formula I".
- the starting material of formula II is known, and may be prepared from s-malic acid of the formula by reduction with BH 3 Me 2 •S followed by treatment with 5% NaBH 4 to obtain a compound of the formula followed by cyclization of this compound with CF 3 CO 2 H to obtain the ⁇ -lactone of formula II.
- the ⁇ -lactone of formula II may be obtained from glucose as described in U.S. Patent 5,292,939, Hollingsworth, which is hereby incorporated by reference.
- An imine of formula III' may be prepared by reacting 4-benzyloxy-benzaldehyde with 4-fluoroaniline in a polar organic solvent such as isopropanol at about room temperature.
- Other imines of the formula III may be prepared in a similar manner, by reacting the appropriate benzaldehyde derivatives and the appropriate aniline derivatives in isopropanol at room temperature for 2 to 3 hours and filtering the reaction mixture to give the product as a solid.
- An enolether of the formula E' may be prepared by reacting 4-fluoro-acetophenone (which is a known compound or may be prepared by known methods) in a solution of lithium diisopropylamide in a polar organic solvent such THF at a temperature in the range of about -30°C to about -35°C, with quenching by addition of Me 3 SiCl, concentration and distillation to obtain the enolether product.
- Other enolethers of formula E may be prepared in a similar manner.
- the reaction mixture was poured slowly into a 10-liter extractor containing 2 liters of 3 N HCl, 1 liter ice and 2.5 liters of EtOAc. The mixture was stirred for 15 min. and separated into layers. The aqueous layer was extracted with 1.0 liter and then with 0.5 liter of EtOAc. The combined organic layers were washed with 4 X 2 liter brine, concentrated, and 250 mL toluene was added to crystallize the trans lactam 4. The solid was filtered and dried at 50°C to give 85.5 g (64% yield) lactam 4. Mp: 119-120°C.
- This quench solution was then cooled to 0°C with an ice bath.
- the aldol mixture was added dropwise into the quench solution at 0°C.
- the quenched mixture was allowed to warm to 15 to 20°C and the layers were separated.
- the aqueous layer was extracted with 1 liter toluene.
- the combined organic layer was washed with 2 X 500 mL and concentrated to about 1 liter for dehydration.
- reaction also could be carried out as follows: A mixture of 1 g of compound 6A in 10 mL of EtOAc, 1 mL of water, and 0.5 (w/w)% of Pd/C (wet) was shaken under 25 psi of H 2 for ca. 4 hrs. The mixture was filtered through celite and washed with toluene. Concentration gave compound 8.
- the chiral catalyst was made following the standard procedure: trimethylboroxine (28 mg, 0.22 mmol) was added into a solution of diphenylprolinol (75 mg, 0.3 mmol) in toluene (5ml) and the resultant solution was heated until refluxing. Toluene was distilled and another 5 ml of toluene was added and distilled out. The residue was used directly in the following reaction.
- the crude compound 6A generated from dehydration step from 80 mmol of aldol condensation product, was dissolved in 120 ml of CH 2 Cl 2 to which 2.2g (2.4 mmol) of the catalyst was added. The mixture was subjected hydrogenation at 60 psi for 18 hr. Concentration of the reaction gave a residue of the product, which was separated by column with hexane and EtOAc (90:10) to give 27.5 g pure product, 71% from aldol condensation product as starting material.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
- This invention provides an improved process for producing azetidinones useful as hypocholesterolemic agents, as disclosed in co-owned, copending PCT Publication WO 95/08532, which is equivalent to U.S. Serial No. 08/617,751, filed March 18, 1996, the disclosure of which is hereby incorporated by reference. More particularly, this invention provides the steps of producing an azetidinone represented by the formula I.
- Tetrahedron, Vol. 47. No. 48, I. Panfil et al., 1991 pages 10087 - 10094 and Chemical Abstracts, vol. 109, no. 5, 1 August 1988 , abstract no. 38139, I. Panfil et., & J. Carbohyd. Chem., vol. 6, no. 3, 1987, pages 463-470 disclose processes wherein a nitrone reacts with the double bond of an unsaturated sugar lactone to form a bicyclic compound, which can be further reacted to give an azetidinone.
-
- R1, R2 and R3 are independently selected from the group consisting of:
- (a) H;
- (b) halo;
- (c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and
- (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl.
-
- In particular, this process is useful for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-4(S)-(4-fluorophenyl)-2-azetidinone.
-
- (a) reacting lactone of formula II with an imine of formula III under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15° to about -35° C, in the presence of a base and optionally in the presence of a cyclization promoter selected from LiCl and LiBr to obtain a chiral diol of formula IV
- (b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
- (c) condensing the aldehyde of formula V in an aprotic anhydrous solvent, in the presence of a Lewis acid and'in a temperature range of -78° to about -20° C, with an enolether of the formula E followed by dehydration to obtain a compound of formula VI
- (d) hydrogenating a compound of formula VI to form a compound of formula VII
- (e) conducting a chiral catalytic reduction of the compound of formula VII with a chiral catalyst in an anhydrous organic solvent, in the presence of a borane, wherein the chiral catalyst is selected from wherein Ph is phenyl, to obtain a compound of formula I
- (f) optionally, when any of R1, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a compound of formula I.
-
- Also claimed are the following processes for preparing intermediates:
- The process of reacting a lactone of formula II with an imine of formula III in the presence of a base and optionally in the presence of a cyclization promoter to obtain a chiral diol of formula IV.
- The process of oxidizing a chiral diol of formula IV to obtain an aldehyde of formula V.
- The process of condensing an aldehyde of formula V with an enolether of formula E, followed by dehydration to obtain a compound of formula VI.
- The process of hydrogenating a compound of formula VI to obtain a ketone of formula VII.
-
-
- Also claimed are the intermediates of formulas IV and VI.
- As used herein the term "lower alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. "Lower alkoxy" refers to alkoxy groups having 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkoxy" means straight or branched alkoxy chains of 1 to 6 carbon atoms.
- "Alkenyl" means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkenyl" means straight or branched alkenyl chains of 1 to 6 carbon atoms. "Alkynyl" means straight or branched carbon chains having one or more triple bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkynyl" means straight or branched alkynyl chains of 1 to 6 carbon atoms.
- Where an alkyl, alkenyl or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.
- "Aryl" (including substituted aryl) means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g. aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2.
- "Aralkyl" means an alkyl group as defined above, in which an aryl group as defined above is substituted for one of the alkyl H atoms, e.g., benzyl, 4-nitro-benzyl' 4-methoxy benzyl and 4-chlorobenzyl.
- "Acid" means an organic acid such as p-toluene sulfonic acid, trifluoroacetic acid or trifluoromethane sulfonic acid. Alternatively "acid" means an inorganic acid such as sulfuric acid, hydrochloric acid or phosphonic acid.
- "Hydrogenation catalyst" means a transition metal or its salt such as Pd/C, Pt/C, Raney nickel, Rh/C, Ru/C, PdO, PtO or (PPh3)3RhCl.
- "Cycloalkenyl" mean a cycloalkane of 4 to 10 carbon atoms with one or more double bonds in the ring.
- "Bn" means benzyl. "BnO" means benzyloxy.
- "Cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. Alternatively, the number of carbon atoms may be specified. Thus, "C3 to C6 cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms.
- "Halogeno" or "hal" or "halogen" refers to fluorine, chlorine, bromine or iodine radicals.
- "Heteroaryl" means a 5- or 6-membered aromatic ring comprising 1 or 2 hetero atoms selected from the groups consisting of nitrogen and oxygen, for example pyridyl, pyrimidyl, imidazolyl, pyrrolyl, furanyl and oxazolyl. All positional isomers for a given heteroaryl group as defined herein are contemplated, for example 2-pyridyl, 3-pyridyl and 4-pyridyl. Heteroaryl also means benzofused heteroaryl radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring as defined above; examples are indolyl, quinolyl, quinazolinyl, quinoxalinyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl.
- "Ph" means phenyl.
- "Suitable inert organic solvent" means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Such solvents used in the various reactions of this invention are identified in the discussion of reaction schemes and in the examples. Typical suitable solvents are halogenated compounds such as chloroform or dichloromethane; heterocyclic compounds such as tetrahydrofuran (THF); 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), dimethylformamide (DMF); dimethylsulfoxide (DMSO), lower alkanols (C1-C6 branched or straight chain alkanols) such as methanol, acetonitrile and carbocyclic aromatics such as toluene.
- "Lewis acid" means an acid such as BF3·etherate, TiCl4 or AlCl3.
-
-
- (a) reacting lactone of formula II with an imine of formula III in the presence of a strong base and optionally in the presence of a cyclization promoter, to obtain a chiral diol of formula IV;
- (b) oxidizing the resulting chiral diol of formula IV to the corresponding aldehyde of formula V, for example with an oxidizing agent such as NaIO4 or H5IO6;
- (c) condensing the aldehyde of formula V with an enolether of the formula E followed by dehydration, for example acid catalyzed dehydration, to obtain a compound of formula VI;
- (d) hydrogenation of a compound of formula VI with a hydrogenation catalyst agent such as hydrogen over palladium or hydrogen and (PPh3)RhCl on carbon to form a compound of formula VII;
- (e) conducting a chiral catalytic reduction of the compound of formula VII with a borane, such as BH3•(CH3)2S or borane-THF complex, and a chiral catalyst such as to obtain a compound of formula I;
- (f) optionally, when any of R1, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group, for example conducting a debenzylation reaction with a hydrogenating agent such as Pd/C/NH3HCO2H or converting an alkoxy group to a hydroxy group by treatment with a Lewis acid to obtain a compound of formula I.
-
- Method A is described in more detail is as follows. In step (a) of Reaction Scheme A, the lactone II is treated in a strong base such as lithium diisopropylamide (LDA) with an imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU, to produce a β-lactam of formula IV. The reaction can be quenched by an acid such as acetic acid, and a trans β-lactam of formula IV can be recovered by extraction followed by crystallization. Because trans β-lactam cyclizes faster than cis β-lactam, formation of a trans isomer is favored. This cyclization can be greatly accelerated by addition of additives such as LiCl or LiBr (in a solvent such as DMF) resulting in further selectivity of trans β-lactam formation. A crystallization step at this stage further improves the ratio of trans to cis β-lactam to 95:5. In this reaction, use of a weaker coordination metal favors the formation of a trans β-lactam of formula IV. Thus, in this reaction, the use of sodium lithium hexamethyldisilyl amide (LiHMDA) as a base favors the formation of a trans β-lactam of formula IV as opposed to the cis isomer, and is preferred as opposed to Et2Zn/LDA or LiN(Pr-i)2. Also in this reaction, a lower temperature favors the formation of a trans β-lactam of formula IV, as opposed to the cis isomer; and thus -35°C, is preferred over -25°C or -15°C.
- In step (b), a β-lactam of formula IV is oxidized by treatment with an oxidizing agent such as NalO4 in a mixture of solvents such as THF and water at a temperature between about 10°C and 25°C, with about 10°C to about 15°C being preferred. The ratio of the oxidizing agent, NalO4, to diol is as follows: if the diol is present at 1.0 equivalent, then the NalO4 is present at 1.0-2.0 equivalents, with 1.5 equivalent being preferred. The organic solvent for the reaction is a polar aprotic solvent such as acetronitrile or THF. The reaction is quenched by adding the reaction mixture to ice water. The resulting aldehyde of formula V is extracted and concentrated for use in the next step of the process.
- In step (c), an aldehyde of formula V is reacted with the enolether of the formula E in an aprotic anhydrous organic solvent such as toluene in the presence of a Lewis acid such as BF3•etherate at a temperature in the range of about -78°C to about -20°C, with about -40°C to about -20°C being preferred. The resulting aldol reaction can be quenched, for example with a mixture of NaHCO3, t-BuOMe and hydrogen peroxide. In this reaction, the ratio of the β-lactam and the enolether can be as follows: if the β-lactam is present at 1.0 equivalent, then the enolether can be present at 0.9 to 1.2 equivalent with 1.0 equivalent being most preferred. The ratio of the β-lactam and BF3•etherate can be as follows: if the β-lactam is present at 1.0 equivalents, then BF3•etherate can be present at 1.0 to 1.5 equivalent, with 1.0 to 1.2 equivalent being preferred.
- The resulting solution containing aldol product is extracted and concentrated for the dehydration step which involves treatment with molecular sieves and an organic acid such as p-toluene sulfonic acid monohydrate. If the aldol product is present at 1.0 equivalent, then the p-toluene sulfonic acid monohydrate can be present at 0.4 to 0.8 equivalent, with 0.5 to 0.6 equivalent being preferred. The solvents which may be employed in this reaction include toluene, t-butyl methyl ether (t-BuOMe), or benzene. The molecular sieves which are used in this reaction are 3A or 4A and are present in the reaction at 100% to 200% weight/weight as compared to the aldol compound. The reaction temperature is about 35°C to about 100°C, with the range of about 45°C to about 60°C being preferred. The resulting compound of formula VI is filtered and concentrated for use in the next step of this process. It will be appreciated that a compound of formula VI is formed with cis and trans stereochemistry. That is, cis and trans about the azetidinone ring as shown by the arrows in these diagrams. Obtaining the compound with the trans stereochemistry is necessary in order to get the desired final products of the invention.
- In step (d), the compound of formula VI is hydrogenated by treatment with a hydrogenating agent such as (Ph3P)3RhCl/H2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH3OH; CH2Cl2; toluene; or benzene. The ratio of hydrogenating agent to the compound of formula VI is as follows: if the compound of formula VI is present at 1 mol %, then the hydrogenating agent is present at 0.1 to 10 mol %, with 0.3 mol % being preferred. The hydrogen atmosphere is present at 5 to 100 psi, with 40 to 60 psi being preferred. The reaction is run for 10 to 30 hours, with 14 to 16 hours being preferred. After extraction and concentration, the resulting compound of formula VII is used in the next step.
- In step (e), the compound of formula VII is chirally reduced by reaction in an anhydrous organic solvent such as CH2Cl2, THF or toluene, in the presence of a borane, such as BH3•(CH3)2S or borane-THF complex, and a chiral reduction catalyst such as at a temperature in the range of about -30° to about 0°C, with a range of about -20° to about -10°C being preferred. The reaction is run for about 1 to about 20 hours, with a range of about 3 to about 10 hours being preferred. The ratio of the compound of formula VII to the chiral reduction catalyst is as follows: if the compound of formula VII is present at 1.0 equivalent, then the catalyst is present in a range of about 5 mol % to 100 mol %, with 5 mol % to 10 mol % being preferred. If the compound of formula VII is present at 1.0 equivalent, then the borane (e.g., BH3•Me2S) is present at 0.7 to 1.0 equivalent, with 0.7 to 0.8 equivalent being most preferred. Concentration, extraction, and crystallization leads to the reduced compound of formula I.
- For compounds of formula I wherein any one of R1, R2 or R3 is benzyloxy or alkoxy, said compounds can be converted to other compounds of formula I wherein R1, R2 or R3 is hydroxy by methods well known in the art. This is important in the preferred process described below, wherein the desired compound of formula I has a hydroxy group at R1, but wherein the hydroxy group must be protected during the process, preferably by a benzyl group. The protected compound of formula I is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCO2NH4 under a hydrogen atmosphere: the concentration of Pd/C is 5% to 20% w/w, with 10-15% w/w being preferred. The ratio of compound of formula I to Pd/C used is 1.0 equivalent of compound of formula I to 2.0 to 5.0 equivalents of Pd/C, with 3.0 to 4.0 equivalent of Pd/C being preferred. Alternatively, hydrogen gas is used in the ranges from 5 psi (pound per square inch) to 100 psi with 20 to 40 psi being preferred. The solvents which can be employed at this stage of the reaction include CH3OH, ethanol and i-propanol. Alkoxy groups can be converted to hydroxy groups by well-known methods, for example by treatment with a Lewis acid. Those skilled in the art will recognize that a reactive substituent at any of R1, R2 or R3, such as hydroxy or amino, can be protected with a suitable protecting group during the claimed process and said protecting group can be removed after the desired compound of formula I is obtained.
- As noted above, when trans β-lactam is formed in step (a), the corresponding cis product is also formed. The cis product is present at this stage of the process in an amount of 5% as compared to the trans product. The cis product may now be purged out by crystallization.
-
-
-
-
-
-
-
-
-
- In another process of the invention, a compound of formula VI" may be converted by the Noyori reduction, i.e. using the catalyst (R)-Ru(BlNAP)Cl2]2.NEt3. to obtain the compound of formula I'". In particular, a compound of formula VI' can be reduced by this method to obtain a compound of formula I".
-
- Alternatively, the γ-lactone of formula II may be obtained from glucose as described in U.S. Patent 5,292,939, Hollingsworth, which is hereby incorporated by reference.
- An imine of formula III' may be prepared by reacting 4-benzyloxy-benzaldehyde with 4-fluoroaniline in a polar organic solvent such as isopropanol at about room temperature. Other imines of the formula III may be prepared in a similar manner, by reacting the appropriate benzaldehyde derivatives and the appropriate aniline derivatives in isopropanol at room temperature for 2 to 3 hours and filtering the reaction mixture to give the product as a solid.
- An enolether of the formula E' may be prepared by reacting 4-fluoro-acetophenone (which is a known compound or may be prepared by known methods) in a solution of lithium diisopropylamide in a polar organic solvent such THF at a temperature in the range of about -30°C to about -35°C, with quenching by addition of Me3SiCl, concentration and distillation to obtain the enolether product. Other enolethers of formula E may be prepared in a similar manner.
-
- To a 5-liter 3 neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added 500 mL of THF, 400 mL of DMPU and 120 mL (0.92 mol) of diisopropylamine. To the cooled mixture at -40 to -45°C was added dropwise 368 mL (0.92 mol) of 2.5 M n-BuLi hexane solution. After 20 minutes, 47 g (0.46 mol) of lactone 3 diluted in 250 mL of THF was introduced and the reaction was agitated at -40 to -45°C for 2 hr. While agitating, 100 g (0.328 mol) of imine was dissolved in 1 liter of DMF and then was added dropwise through the addition funnel into the reaction mixture at -40 to -45°C (30 min.). The reaction was maintained at -25 to -30°C for 14 to 18 hrs and warmed to -13 to -17°C for another 4 hrs as followed by HPLC. 14 g of LiCl was dissolved in 400 mL DMF in a 500 mL flask and added into the reaction mixture. After another 2 hrs at -15°C, 200 mL of HOAc was added to quench the reaction.
- The reaction mixture was poured slowly into a 10-liter extractor containing 2 liters of 3 N HCl, 1 liter ice and 2.5 liters of EtOAc. The mixture was stirred for 15 min. and separated into layers. The aqueous layer was extracted with 1.0 liter and then with 0.5 liter of EtOAc. The combined organic layers were washed with 4 X 2 liter brine, concentrated, and 250 mL toluene was added to crystallize the trans lactam 4. The solid was filtered and dried at 50°C to give 85.5 g (64% yield) lactam 4. Mp: 119-120°C. 1H NMR (CDCl3) 7.38 (m, 5H), 7.22 (m, 4H), 6.90 (m, 4H), 5.04 (d, J=2.0, 1H), 5.02 (s, 2H), 4.21 (m, 1H), 3.70 (m, 1H), 3.6 (m,1H), 3.52 (d, J=5.0, 1H), 3.15 (dd, J=5.2, 2.0Hz), 2.85 (t, J=5.3, 1H). 13C NMR (CDCl3) 165.5, 160.7, 159.0, 157.5, 136.7, 133.6, 133.5, 129.3, 128.7, 128.2, 127.6, 127.4, 118.8, 118.6, 116.0, 115.5, 70.1, 69.5, 62.9, 56.8. HRMS: 408.1619 (MH+); Calc'd: 408.1611. [α] 25 / D69.78 (c=0.121, THF). Anal.Calc'd for C24H23FNO4: C, 70.75; H, 5.44; N, 3.44. Found: C, 70.57; H, 5.56; N, 3.41.
- To a 2 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added sequentially 100 g (0.246 mmol) of lactam 4 and 800 mL of CH3CN. The mixture was cooled to 10°C with an ice bath. 63 g (0.295 mmol) of NalO4 was dissolved in 800 mL of water in a 1 liter flask and transfered into the addition funnel. The NalO4 solution was added into the reaction mixture at such a rate to maintain the temperature below 20°C (20 min.). After addition, the reaction was warmed to room temperature (r.t.) and stirred for 1 to 2 hrs as followed by NMR. The reaction was quenched into a 6 liter extractor containing 1.5 liters of ice-brine and 1.5 liters of toluene. The layers were stirred, separated and the aqueous layer was extracted with 500 mL of toluene. The combined organic layer was washed with 2 X 500 mL brine and concentrated to about 500 mL for the next reaction. MS: 376( MH+), 265, 239. 1H NMR (CDCl3) 9.82 (d, J=1.3Hz, 1H), 7.31 (m, 5H), 7.17 (m, 4H), 6.88 (m, 4H), 5.32 (d, J=2.4HZ, 1H), 4.98 (s, 2H), 4.15 (dd, J=2.4, 1.3Hz, 1H).
- To a 1 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added at r.t. a solution of 100 g (0.267mmol) of aldehyde 5 (from Example 2) in 500 mL of toluene and 32 mL (0.267 mmol) of BF3•etherate. The mixture was cooled to -30°C with a dry-ice bath. To the cooled mixture was added 56 g (0.267 mmol) of enolether dropwise. The aldol reaction is completed in 5 min. To another 5 liter extractor were added 1 liter of saturated NaHCO3 solution, 2 liters of t-BuOMe, and 150 mL of hydrogen peroxide (30%). This quench solution was then cooled to 0°C with an ice bath. The aldol mixture was added dropwise into the quench solution at 0°C. The quenched mixture was allowed to warm to 15 to 20°C and the layers were separated. The aqueous layer was extracted with 1 liter toluene. The combined organic layer was washed with 2 X 500 mL and concentrated to about 1 liter for dehydration.
- To the 1 liter toluene solution of aldol product obtained above were added 200 g of molecular sieves and 25 g (0.133 mmol) of p-toluenesulfonic acid monohydrate. This mixture was heated to 40 to 50°C and monitored by NMR (2 to 4 hrs.). The reaction was cooled to 0°C and filtered through a pad of MgSO4 and then 100 g silica gel. The filtrate was concentrated for the next step. Alternatively, the concentrated solution was added to 400 mL of heptane to precipitate the double bond product (99 g, 7.5% overall yields). MS: 496 (MH+), 359, 305, 238. 1H NMR 8.01 (dd, J=8.5, 5.5Hz, 1H), 7.40 (m, 7H), 7.30 (m, 6H), 7.18 (m, 2H), 7.22 (d, J=8.6, 1H), 6.98 (t, J=8.5Hz, 1H), 5.08 (s, 2H), 4.88 (d, J=2.4, 1H), 4.00 (m, 1H).
- To a 1 liter Parr pressure bottle were added 0.8 g of Palladium on carbon (10%), 1.6 g (19.0 mmol) of NaHCO3, 16 g (32.3 mmol) of compound 6A in 80 mL of EtOAc and 80 mL of CH3OH. The bottle was shaken under 30 psi of hydrogen pressure for 2 to 3 hrs as followed by TLC and HPLC. The reaction mixture was filtered through a pad of celite and washed with 200 mL toluene. The filtrate was washed in a 1 liter extractor with 200 mL brine and 2 mL of 3 N HCl. After separation of the layers, the organic layer was washed with 2 X 200 mL brine.
Concentration gave 11.8 g (90% yield) of compound 8. - (The reaction also could be carried out as follows: A mixture of 1 g of compound 6A in 10 mL of EtOAc, 1 mL of water, and 0.5 (w/w)% of Pd/C (wet) was shaken under 25 psi of H2 for ca. 4 hrs. The mixture was filtered through celite and washed with toluene. Concentration gave compound 8.
- MS: 408 (MH+), 297. 1H NMR (CDCl3) 7.95 (dd, J=8.6, 5.5Hz, 2H), 7.13-7.22 (m, 4H), 7.09 (t, J=8.6, 2H), 6.91 (t, J=8.6, 2H), 6.80 (d, J=8.6Hz, 2H), 4.65 (d, J=2.1, 1H), 3.26 (m, 1H), 2.33 (s, 1H), 2.25 (m, 1H). 13C (CDCl3) 197.7, 167.7, 164.5, 160.7, 157.5, 156.3, 133.8, 133.0, 130.9, 130.7, 129.2, 127.5, 118.6, 118.5, 116.2, 116.1, 116.0, 115.8, 115.7, 61.3, 59.7, 35.6, 23.3. Anal. Calc'd. for C24H19NF2O3•1/2 H2O: C, 69.75; H, 4.47; N, 2.95; F, 9.11. Found: C, 69.23; H, 4.80; N, 3.36; F, 9.13.
- The chiral catalyst was made following the standard procedure: trimethylboroxine (28 mg, 0.22 mmol) was added into a solution of diphenylprolinol (75 mg, 0.3 mmol) in toluene (5ml) and the resultant solution was heated until refluxing. Toluene was distilled and another 5 ml of toluene was added and distilled out. The residue was used directly in the following reaction.
- To a 50 mL oven-dried flask with a magnetic stirrer were added 2.4 g (5.9 mmol) of compound 8, 10 mL CH2Cl2, and 0.62 g (3.0 mmol) of bistrimethylsilyl urea (BSU). After 0.5 hr, the reaction was filtered directly into another 50 mL oven-dried flask containing 0.05 eq. of the chiral catalyst at -20°C. To this was added 2.3 mL (4.7 mmol) of 2 N BH3•Me2S. The reaction was stirred at -15 to -20°C and monitored by TLC and HPLC (3 to 5 hrs). 10 mL methanol/HCl was added, followed by concentration. Water and t-BuOMe were added to the residue and it was extracted with t-BuOMe (x2) to give a crude product solution. Concentration of t-BuOMe lead to the recovery of >50% catalyst as the HCl salt after filtration. Crystallization of crude product from Isopropanol/H2O afforded 1.9 g of compound 8A. 1H NMR(DMSO) 9.54 (s, 1H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, J=4.6Hz, 1H), 4.82 (d, J=2.1Hz, 1H), 4.50 (m, 1H), 3.10 (m, 1H), 1,70-1.9 (m, 4H). 13C NMR(DMSO) 167.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1, 134.0, 128.0, 127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5; 24.6.
- The crude compound 6A, generated from dehydration step from 80 mmol of aldol condensation product, was dissolved in 120 ml of CH2Cl2 to which 2.2g (2.4 mmol) of the catalyst was added. The mixture was subjected hydrogenation at 60 psi for 18 hr. Concentration of the reaction gave a residue of the product, which was separated by column with hexane and EtOAc (90:10) to give 27.5 g pure product, 71% from aldol condensation product as starting material. 1H NMR (CDCl3) 7.98 (dd, J=8.5, 5.5Hz, 1H), 7.41 (m, 5H), 7.25 (m, 4H), 7.12 (t, J=8.5, 2H), 6.55 (m, 4H), 5.04 (s, 2H), 4.68 (d, J=2.1, 1H), 3.65 (m, 1H), 3.28 (m, 1H), 3.16 (m, 1H), 2.40 (m, 1H), 2.28 (m, 1H).
- To a 250 mL oven-dried flask with a magnetic stirrer were added 6.2 g (12.5 mmol) of compound 6B and 60 mL of CH2Cl2. To the resulting solution at -20°C were added sequentially 0.1 equivalent of the chiral catalyst and 6.3 mL (12.5 mmol) of 2.0 N BH3•(CH3)2S over 2 h. The reaction was allowed to warm to 0°C, it was stirred at that temperature for 1 h and quenched with CH3OH. The quenched solution was concentrated and extracted with CH2Cl2. The organic layer was concentrated and the residue was recrystallized from EtOAc and hexanes to give 4.1 g (70%) of 8B. The e.e. was determined by HPLC and found to be 93%. 1H NMR (CDCl3): δ 7.45-7.15 (m, 11H), 7.00-6.80 (m, 6H), 4.98 (s, 2H), 4.70-4.60 (m, 1H), 4.50 (d, 1H), 3.05-2.97 (m, 1H), 2.20-2.10 (m, 1H), 1.95-1.75 (m, 4H).
- To a flask were added Pd-C (10%) (1g, 5% by w/w), ammonium bicarbonate (11.4 g, 181 mmole), compound 8B (18.1 g, 36.3 mmole) and CH3OH (250 mL) carefully at r.t. under N2. HOAc was added to adjust the pH to 3-5 and the resultant mixture was heated at 45 to 55°C until the reaction finished as determined by TLC (about 2-3hr): During the reaction, the pH was controlled in the range of 3-5 by adding HOAc. The reaction was filtered and the solvent evaporated. The residue was dissolved in t-BuOMe and washed with water. After drying over Na2SO4 and evaporating the solvent, the product was purified by recrystallization in t-BuOMe/heptane and CH3OH/water to give 11.75 g (79%). 1H NMR (DMSO): 9.54 (s, 1H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, J=4.6Hz, 1H), 4.82 (d, J=2.1 Hz, 1H), 4.50 (m, 1H), 3.10 (m, 1H), 1,70-1.9 (m, 4H). 13C NMR (DMSO) 167.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1, 134.0, 128.0, 127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5, 24.6. (Cyclooctadienyl)ruthenium dichloride (107 mg, 0.38 mmol) and (R)-2,2'-bis)diphenylphosphino)-1,1'-binaphthyl (BINAP) (250 mg, 0.40 mmol) were placed in a flask and connected to Schlenck apparatus with another flask at the opposite end. The entire apparatus was evacuated, then filled with N2. Toluene (10 mL) and Et3N (1 mL), after deoxygenation several times, was charged into the lower flask, which was then heated to 140-145°C for 4 h. After cooling to r.t., red solid precipitated out of solution. The solid was filtered and washed with degased toluene inside of the apparatus under N2. The entire apparatus was evacuated and the solid was dried.
- Compound 6A (50 mg, 0.1 mmol), the catalyst, [(R)-Ru(BlNAP)Cl2]2.NEt3, prepared above (<10 mg, <0.01 mmol) and CH3OH (50 mL) with 1 drop of 2N HCl were charged in an autoclave under N2. The reaction was subjected to 850 psi N2 at 80°C for 48 h. Major product (I") was found and matched in TLC and HPLC profile with the product of Example 5.
- To a mixture of 300 mg (0.61 mmol) of 6A and 0.1 equivalent of the chiral catalyst in 5 mL of CH2Cl2 at -15°C, 0.21 mL (0.4 mmol) of 2.0 N BH3•(CH3)2S was added dropwise over 5 min. The reaction was allowed to warm to 0°C, it was stirred for 45 min. and quenched with CH3OH. Concentration, followed by chromatography gave compound Xl. The e.e. was determined to be 75%. 1H NMR (CDCl3): δ 7.55-6.82 (m, 18H), 5.95 (d, 1H), 5.15 (d, 1H), 4.98 (s, 2H), 4.65 (d, 1H), 3.65 (d, 1H).
Claims (14)
- A process for producing a compound of the formula wherein:R1, R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl; wherein in item (c) and (d), respectively above
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen; cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising(a) reacting lactone of formula II with an imine of formula III under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15° to about -35° C, in the presence of a base and optionally in the presence of a cyclization promoter selected from LiCI and LiBr to obtain a chiral diol of formula IV(c) condensing the aldehyde of formula V in an aprotic anhydrous solvent, in the presence of a Lewis acid and in a temperature range of -78° to about -20° C, with an enolether of the formula E followed by dehydration to obtain a compound of formula VI(e) conducting a chiral catalytic reduction of the compound of formula VII with a chiral catalyst in an anhydrous organic solvent, in the presence of a borane, wherein the chiral catalyst is selected from wherein Ph is phenyl, to obtain a compound of formula I;(f) optionally, when any of R1, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a compound of formula I. - A process according to claim 1 for producing the compound of the formula comprising(a) reacting lactone of formula II with an imine of formula III' under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15° to about -35° C, in the presence of a base and optionally in the presence of a cyclization promoter selected from LiCl and LiBr to obtain a chiral diol of formula IV'(c) condensing the aldehyde of formula V in an aprotic anhydrous solvent, in the presence of a Lewis acid and in a temperature range of -78° to about-20° C, with an enolether of the formula E' followed by dehydration to obtain a compound of formula VI'(e) conducting a chiral catalytic reduction of the compound of formula VII with a chiral catalyst in an anhydrous organic solvent, in the presence of a borane, wherein the chiral catalyst is selected from to obtain a compound of formula I' and(f) debenzylating the compound of formula I'.
- A process for the preparation of a compound of the formula wherein R1 and R2 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2; aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms; heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen; cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising reacting a lactone of the formula with an imine of the formula wherein R1 and R2 are as defined above. - A compound of the formula wherein R1 and R2 are independently selected from the group-consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2; aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen; cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. - A process for preparing a compound of the formula V wherein R1 and R2 are Independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2;
aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising oxidizing a chiral diol of formula IV wherein R1 and R2 are as defined above. - A process for preparing a compound of formula VI wherein R1, R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2;
aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising condensing an aldehyde of formula V wherein R1 and R2 are as defined above, with an enolether of the formula E wherein R3 is as defined above, followed by dehydration. - A compound of the formula wherein R1, R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2; aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers, - A process for preparing a compound of the formula VII wherein R1, R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2;
aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising hydrogenating a compound of formula VI - A process for preparing a compound of the formula X wherein R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2;
aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising hydrogenating a compound of the formula VI" - A process for preparing a compound of the formula XI wherein R2 and R3 are independently selected from the group consisting of:(a) H;(b) halo;(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and(d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
aryl means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring, with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2;
aralkyl means a C1-6 alkyl group, in which an aryl group as defined above is substituted for one of the H atoms;
heteroaryl means a 5- or 6-membered aromatic ring comprising 1 to 2 hetero atoms selected from the groups consisting of nitrogen and oxygen;
cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers; comprising chirally reducing the compound of formula VI"
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US655785 | 1996-05-31 | ||
US08/655,785 US5739321A (en) | 1996-05-31 | 1996-05-31 | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
PCT/US1997/009666 WO1997045406A1 (en) | 1996-05-31 | 1997-05-28 | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0906278A1 EP0906278A1 (en) | 1999-04-07 |
EP0906278B1 true EP0906278B1 (en) | 2002-10-16 |
Family
ID=24630339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97928831A Expired - Lifetime EP0906278B1 (en) | 1996-05-31 | 1997-05-28 | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
Country Status (14)
Country | Link |
---|---|
US (1) | US5739321A (en) |
EP (1) | EP0906278B1 (en) |
JP (1) | JP3155759B2 (en) |
AR (1) | AR007314A1 (en) |
AT (1) | ATE226191T1 (en) |
AU (1) | AU3299497A (en) |
CA (1) | CA2255662C (en) |
CO (1) | CO4770966A1 (en) |
DE (1) | DE69716426T2 (en) |
DK (1) | DK0906278T3 (en) |
ES (1) | ES2185026T3 (en) |
PT (1) | PT906278E (en) |
WO (1) | WO1997045406A1 (en) |
ZA (1) | ZA974678B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102531986A (en) * | 2012-02-23 | 2012-07-04 | 苏州朗科生物技术有限公司 | Preparation method for ezetimibe |
WO2012155932A1 (en) | 2011-05-17 | 2012-11-22 | Pharmathen S.A. | Improved process for the preparation of ezetimibe |
CN103044305A (en) * | 2013-01-24 | 2013-04-17 | 上海现代制药股份有限公司 | Preparation method of ezetimibe intermediate |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
PT1137634E (en) * | 1998-12-07 | 2005-10-31 | Schering Corp | PROCESS FOR SYNTHESIS OF AZETIDINONES |
AU2002216097B2 (en) | 2000-12-21 | 2006-09-07 | Sanofi-Aventis Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
DE60216890T2 (en) * | 2001-01-26 | 2007-08-30 | Schering Corp. | COMBINATIONS OF A STARTER ABSORPTION HEMMER AND A PPAR ACTIVATOR FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
CA2442219C (en) | 2001-03-28 | 2007-09-11 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
AU2002336609B2 (en) * | 2001-09-21 | 2006-08-24 | Merck Sharp & Dohme Corp. | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
US7671047B2 (en) | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7176193B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7176194B2 (en) | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
JP4589919B2 (en) * | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | Substituted azetidinone compounds, their formulations and uses for the treatment of hypercholesterolemia |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7459442B2 (en) * | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
AR041089A1 (en) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS |
AU2003259547A1 (en) * | 2003-07-31 | 2005-02-14 | Hetero Drugs Limited | Ezetimibe polymorphs |
EP1687287A1 (en) | 2003-11-24 | 2006-08-09 | Hetero Drugs Limited | A novel process for ezetimibe intermediate |
AU2004303742B2 (en) * | 2003-12-23 | 2008-06-19 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
EP1723414A4 (en) * | 2004-01-16 | 2008-03-26 | Merck & Co Inc | Npc1l1 (npc3) and methods of identifying ligands thereof |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
WO2006026273A2 (en) * | 2004-08-25 | 2006-03-09 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
EP1817280A1 (en) * | 2004-12-03 | 2007-08-15 | Teva Pharmaceutical Industries Ltd. | Ezetimibe polymorphs |
US20060234996A1 (en) * | 2005-04-14 | 2006-10-19 | Itai Adin | Novel crystalline form of ezetimibe and processes for the preparation thereof |
CN101243072A (en) * | 2005-06-20 | 2008-08-13 | 先灵公司 | Piperidine derivatives useful as histamine H3 antagonists |
SA06270191B1 (en) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions |
AR054482A1 (en) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS |
US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
WO2007030721A2 (en) * | 2005-09-08 | 2007-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe |
AU2006304836A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
HU0501164D0 (en) * | 2005-12-20 | 2006-02-28 | Richter Gedeon Vegyeszet | New industrial process for the production of ezetimibe |
US20090227786A1 (en) * | 2005-12-22 | 2009-09-10 | Ana Gavalda I Escude | Processes for preparing intermediate compounds useful for the preparation of ezetimibe |
WO2007100807A2 (en) | 2006-02-24 | 2007-09-07 | Schering Corporation | Npc1l1 orthologues |
WO2007108007A1 (en) * | 2006-03-23 | 2007-09-27 | Unichem Laboratories Limited | A process for the preparation of ezetimibe via a novel intermediate |
AR060216A1 (en) * | 2006-03-29 | 2008-06-04 | Medichem Sa | PROCESSES TO PREPARE EZETIMIBE AND USEFUL INTERMEDIATE COMPOUNDS FOR PREPARATION |
AR060623A1 (en) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD |
JP2009503119A (en) * | 2006-08-29 | 2009-01-29 | テバ ファーマシューティカル インダストリーズ リミティド | Purify (3R, 4S) -4- (4-hydroxy protected-phenyl) -1- (4-fluorophenyl) -3- [3- (4-fluorophenyl) -3-oxopropyl] azetidin-2-one how to |
CA2661404A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
WO2008032338A2 (en) * | 2006-09-11 | 2008-03-20 | Manne Satyanarayana Reddy | Improved process for the preparation of ezetimibe and its intermediates |
US20100069347A1 (en) * | 2006-11-02 | 2010-03-18 | Morriello Gregori J | Heterocyclyl-substituted anti-hypercholesterolemic compounds |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
US20080319221A1 (en) | 2007-06-22 | 2008-12-25 | Bernd Junker | Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids |
DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia |
CZ305066B6 (en) * | 2008-02-25 | 2015-04-22 | Zentiva, K.S. | Process for preparing (3R, 4S)-l-(4-fiuorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone |
EP2128133A1 (en) * | 2008-05-26 | 2009-12-02 | Lek Pharmaceuticals D.D. | Ezetimibe process and composition |
PL387331A1 (en) | 2009-02-24 | 2010-08-30 | Instytut Chemii Organicznej Polskiej Akademii Nauk | Method of manufacturing beta-lactam aldehyde compound, the intermediate compound, method of manufacturing the intermediate compound and application of the intermediate compound |
CA2757722C (en) | 2009-04-01 | 2018-05-22 | Matrix Laboratories Ltd. | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
US9040262B2 (en) | 2010-05-04 | 2015-05-26 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
ES2372460B1 (en) | 2010-07-09 | 2012-11-16 | Moehs Ibérica S.L. | NEW METHOD FOR THE PREPARATION OF EZETIMIBA. |
CN102477008B (en) * | 2010-11-22 | 2014-05-21 | 沈阳药科大学 | Method for synthesizing ezetimibe |
WO2012076030A1 (en) * | 2010-12-10 | 2012-06-14 | Pharmathen S.A. | Process for the preparation of intermediate compounds useful in the preparation of ezetimibe |
PL231215B1 (en) | 2011-06-15 | 2019-02-28 | Inst Chemii Organicznej Polskiej Akademii Nauk | Process for the preparation of substituted azetidinones and intermediates for the synthesis thereof |
CN103086938A (en) * | 2011-10-28 | 2013-05-08 | 沈阳药科大学 | Ezetimibe synthesis method |
CN103570574B (en) | 2012-07-20 | 2016-04-13 | 中国科学院上海有机化学研究所 | Intermediate used in a kind of synthetic method of ezetimibe and the method |
WO2015039675A1 (en) | 2013-09-23 | 2015-03-26 | Pharmathen S.A. | Novel process for the preparation of ezetimibe intermediates |
CN103739537B (en) * | 2013-12-24 | 2015-05-20 | 连云港恒运医药科技有限公司 | New synthesis method of ezetimibe |
CN104072398B (en) * | 2014-07-03 | 2016-02-03 | 河南省科学院化学研究所有限公司 | A kind of method of synthesizing Ezetimibe |
JP2016145173A (en) * | 2015-02-09 | 2016-08-12 | 株式会社トクヤマ | Method for producing (3r,4s)-1-(4-fluorophenyl)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl]-(4-hydroxyphenyl)-2-azetidinone |
CN107098841A (en) * | 2016-02-19 | 2017-08-29 | 常州方楠医药技术有限公司 | Intermediate used in the preparation method and this method of a kind of Ezetimibe |
CN107033051A (en) * | 2017-06-08 | 2017-08-11 | 武汉励合生物医药科技有限公司 | A kind of preparation method of ezetimibe |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
-
1996
- 1996-05-31 US US08/655,785 patent/US5739321A/en not_active Expired - Lifetime
-
1997
- 1997-05-28 JP JP54307797A patent/JP3155759B2/en not_active Expired - Fee Related
- 1997-05-28 ZA ZA9704678A patent/ZA974678B/en unknown
- 1997-05-28 EP EP97928831A patent/EP0906278B1/en not_active Expired - Lifetime
- 1997-05-28 WO PCT/US1997/009666 patent/WO1997045406A1/en active IP Right Grant
- 1997-05-28 AT AT97928831T patent/ATE226191T1/en active
- 1997-05-28 ES ES97928831T patent/ES2185026T3/en not_active Expired - Lifetime
- 1997-05-28 PT PT97928831T patent/PT906278E/en unknown
- 1997-05-28 DE DE69716426T patent/DE69716426T2/en not_active Expired - Lifetime
- 1997-05-28 CA CA002255662A patent/CA2255662C/en not_active Expired - Fee Related
- 1997-05-28 AU AU32994/97A patent/AU3299497A/en not_active Abandoned
- 1997-05-28 DK DK97928831T patent/DK0906278T3/en active
- 1997-05-28 AR ARP970102280A patent/AR007314A1/en unknown
- 1997-05-28 CO CO97029256A patent/CO4770966A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012155932A1 (en) | 2011-05-17 | 2012-11-22 | Pharmathen S.A. | Improved process for the preparation of ezetimibe |
CN102531986A (en) * | 2012-02-23 | 2012-07-04 | 苏州朗科生物技术有限公司 | Preparation method for ezetimibe |
CN103044305A (en) * | 2013-01-24 | 2013-04-17 | 上海现代制药股份有限公司 | Preparation method of ezetimibe intermediate |
Also Published As
Publication number | Publication date |
---|---|
DE69716426D1 (en) | 2002-11-21 |
AR007314A1 (en) | 1999-10-27 |
ZA974678B (en) | 1997-11-28 |
US5739321A (en) | 1998-04-14 |
AU3299497A (en) | 1998-01-05 |
DE69716426T2 (en) | 2003-08-14 |
JPH11511754A (en) | 1999-10-12 |
EP0906278A1 (en) | 1999-04-07 |
CO4770966A1 (en) | 1999-04-30 |
JP3155759B2 (en) | 2001-04-16 |
CA2255662C (en) | 2005-11-08 |
ES2185026T3 (en) | 2003-04-16 |
PT906278E (en) | 2003-01-31 |
ATE226191T1 (en) | 2002-11-15 |
WO1997045406A1 (en) | 1997-12-04 |
CA2255662A1 (en) | 1997-12-04 |
DK0906278T3 (en) | 2003-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0906278B1 (en) | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones | |
US6096883A (en) | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones | |
AU678605B2 (en) | Processes for the preparation of pesticides and intermediates | |
EP0533265A1 (en) | Process of making substituted azetidinones | |
KR100567941B1 (en) | Method for producing -cis-3-hydroxy-1-methyl-4-2,4,6-trimethoxyphenyl-piperidine | |
JP2001504081A (en) | Preparation of optically enriched 4-aryl-3-hydromethyl-substituted piperidines as intermediates for paroxetine synthesis | |
EP0446832B1 (en) | Process for the preparation of castanospermine | |
US6437136B2 (en) | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine | |
KR100778953B1 (en) | Cyclic ketones, their preparation and their use in the synthesis of amino acids | |
EP0911335B1 (en) | Method for producing furopyridine derivatives and intermediate compounds | |
US5380849A (en) | Process for optically pure decahydroisoqiunolines | |
JPS6328423B2 (en) | ||
JP2012520291A (en) | Preparation of ramelteon | |
KR890000419B1 (en) | Process for production of encanide | |
JP2002533325A (en) | Process for producing aryl piperidine carbinol intermediates and derivatives | |
EP0955287A1 (en) | Propynyl compounds | |
CZ305024B6 (en) | Process for preparing quinoline carboxaldehyde derivatives and intermediates thereof | |
EP0664293A1 (en) | 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo | |
KR100684081B1 (en) | Preparation of optically active 3,4-dihydrobenzoxazine derivative | |
JPH0633264B2 (en) | Method for producing O-substituted teriliverin | |
JPH0313230B2 (en) | ||
WO1988001619A1 (en) | 1'-methyl-beta-lactam compounds and their production | |
JPH0633265B2 (en) | Method for producing teribarin | |
CA2138745A1 (en) | 2-phenyl-7-azabicycloheptanes and 6 phenyl-8-azabicyclooctanes | |
MXPA00006631A (en) | Method for producing (-)cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl)-piperidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981105 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 981105;LV PAYMENT 981105;RO PAYMENT 981105 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STEINMAN, MARTIN Inventor name: SCHUMACHER, DORIS, P. Inventor name: WONG, YEE-SHING Inventor name: CHEN, XING Inventor name: WU, GUANG-ZHONG |
|
17Q | First examination report despatched |
Effective date: 20010530 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 19981105;LV PAYMENT 19981105;RO PAYMENT 19981105 |
|
REF | Corresponds to: |
Ref document number: 226191 Country of ref document: AT Date of ref document: 20021115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69716426 Country of ref document: DE Date of ref document: 20021121 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20021205 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20020404264 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2185026 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20030717 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SCHERING CORPORATION Free format text: SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NEW JERSEY 07033-0530 (US) -TRANSFER TO- SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NEW JERSEY 07033-0530 (US) |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: MERCK SHARP & DOHME CORP. Free format text: SCHERING CORPORATION#2000 GALLOPING HILL ROAD#KENILWORTH, NEW JERSEY 07033-0530 (US) -TRANSFER TO- MERCK SHARP & DOHME CORP.#126 EAST LINCOLN AVENUE#RAHWAY, NEW JERSEY 07065 (US) |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: TD Effective date: 20120924 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: MERCK SHARP & DOHME CORP. Effective date: 20121023 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120518 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: HC Ref document number: 226191 Country of ref document: AT Kind code of ref document: T Owner name: MERCK SHARP & DOHME CORP., US Effective date: 20130117 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20120426 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD Owner name: SCHERING CORPORATION, US Effective date: 20130319 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 69716426 Country of ref document: DE Representative=s name: VON KREISLER SELTING WERNER - PARTNERSCHAFT VO, DE Effective date: 20130516 Ref country code: DE Ref legal event code: R082 Ref document number: 69716426 Country of ref document: DE Representative=s name: VON KREISLER SELTING WERNER, DE Effective date: 20130516 Ref country code: DE Ref legal event code: R081 Ref document number: 69716426 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., RAHWAY, US Free format text: FORMER OWNER: SCHERING CORP., 07033-0530 KENILWORTH, NEW JERSEY, US Effective date: 20130516 Ref country code: DE Ref legal event code: R081 Ref document number: 69716426 Country of ref document: DE Owner name: MERCK SHARP & DOHME CORP., US Free format text: FORMER OWNER: SCHERING CORP., 07033-0530 KENILWORTH, US Effective date: 20130516 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20130507 Year of fee payment: 17 Ref country code: CH Payment date: 20130426 Year of fee payment: 17 Ref country code: DK Payment date: 20130424 Year of fee payment: 17 Ref country code: IE Payment date: 20130510 Year of fee payment: 17 Ref country code: LU Payment date: 20130605 Year of fee payment: 17 Ref country code: GB Payment date: 20130425 Year of fee payment: 17 Ref country code: DE Payment date: 20130531 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20130514 Year of fee payment: 17 Ref country code: FI Payment date: 20130503 Year of fee payment: 17 Ref country code: IT Payment date: 20130520 Year of fee payment: 17 Ref country code: FR Payment date: 20130531 Year of fee payment: 17 Ref country code: GR Payment date: 20130426 Year of fee payment: 17 Ref country code: PT Payment date: 20130429 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20130604 Year of fee payment: 17 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69716426 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20141128 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20141201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20140531 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 226191 Country of ref document: AT Kind code of ref document: T Effective date: 20140528 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM9D Effective date: 20140528 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140528 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140529 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141128 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141203 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20020404264 Country of ref document: GR Effective date: 20141203 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69716426 Country of ref document: DE Effective date: 20141202 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141202 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140528 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140602 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140529 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 |